India, June 24 -- Natera Inc. (NTRA), a precision medicine company, on Wednesday announced the approval of the Signatera MRD test by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for diagnosing colorectal cancer.
Colorectal cancer (CRC) is prevalent in Japan, with over 150,000 people diagnosed annually in the country.
Signatera is a minimal residual disease (MRD) test that was approved by the U.S. FDA in May 2026 as a companion diagnostic to adjuvant atezolizumab immunotherapy in bladder cancer. It is also being evaluated as a diagnostic tool in bladder cancer.
The approval was based on the strength of results from the GALAXY trial, which demonstrated that MRD-positive patients benefitted significantly more from adjuvant...